Crohn's disease — maintenance & biologic therapy
Crohn's maintenance · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Transmural, potentially stricturing/penetrating disease requiring maintenance immunosuppression after induction. Early advanced therapy ('top-down') is favoured in high-risk patients to prevent complications and surgery.
Red flags
- Obstructive symptoms (stricture)
- Abdominal mass, fever, or features of abscess/fistula
- Significant weight loss / failure to thrive
- New perianal sepsis
Assessment
Differential diagnosis
- Ulcerative colitis
- Intestinal TB / Yersinia
- Behçet's disease
- NSAID enteropathy
- Ischaemic/segmental colitis
- Lymphoma
- Functional symptoms overlapping remission
Investigations
- Faecal calprotectin for monitoring
- CRP, FBC, albumin, ferritin, B12, vitamin D
- Colonoscopy/ileoscopy with biopsy for mucosal healing
- MR enterography for small-bowel/stricturing/penetrating disease
- Thiopurine metabolites; therapeutic drug monitoring of biologics
- Hepatitis B/C, TB (IGRA), VZV before immunosuppression
Management
- Define phenotype (inflammatory, stricturing, penetrating) and location; identify high-risk features (young, deep ulcers, perianal, early surgery)
- Assess prognosis — favour early advanced therapy in high-risk disease
- Do NOT use 5-ASA as effective Crohn's maintenance (limited efficacy)
- Use a thiopurine or methotrexate as immunomodulator, often combined with a biologic
- Start a biologic — anti-TNF (infliximab/adalimumab), ustekinumab, vedolizumab, or risankizumab
- Complete infection screening and vaccination before starting immunosuppression
- Stop smoking — the single most important modifiable factor in Crohn's
- Target deep remission (symptomatic + biochemical/endoscopic healing); use therapeutic drug monitoring
- Image strictures to distinguish inflammatory from fibrotic before escalating vs endoscopic/surgical treatment
- Replace micronutrient deficiencies (iron, B12, vitamin D) and optimise nutrition
- Plan post-operative prophylaxis after resection and ongoing surveillance
Drugs & doses
Azathioprine 2–2.5 mg/kg PO once daily
Methotrexate 15–25 mg SC/IM once weekly (with folic acid 5 mg weekly)
Infliximab 5 mg/kg IV at 0, 2, 6 weeks then 8-weekly
Adalimumab 160/80 mg SC induction then 40 mg every 2 weeks
Ustekinumab IV weight-based induction then 90 mg SC every 8 weeks
Risankizumab 600 mg IV induction then 360 mg SC maintenance
Disposition
Specialist IBD clinic with MDT (radiology, surgery, dietitian) and nurse-led biologic monitoring.
Complications & pitfalls
- Fibrotic strictures and obstruction
- Fistulae and intra-abdominal abscess
- Malnutrition and micronutrient deficiency
- Opportunistic infection and lymphoma risk from immunosuppression
- Short-bowel syndrome after repeated resection
Exam pearls
- 5-ASA is ineffective for Crohn's maintenance — reserve the immunomodulators and biologics
- Early 'top-down' biologic therapy in high-risk disease reduces complications and surgery
- Smoking cessation is as important as any drug in Crohn's
- MR enterography differentiates inflammatory (treatable) from fibrotic (needs dilatation/surgery) strictures
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.